Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults

Psychopharmacology

Volumn 227, Issue 1, 2013, Pages 165-176

  Chou, Hsun Hua ^a   Talledo, Jo A ^a   Lamb, Sarah N ^a   Thompson, Wesley K ^a   Swerdlow, Neal R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine; Cognition; MATRICS; MCCB; Neurocognition; Schizophrenia

Indexed keywords

DEXAMPHETAMINE; PLACEBO;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; PERSONALITY TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; TEST RETEST RELIABILITY;

ADOLESCENT; ADULT; AMPHETAMINE; BLOOD PRESSURE; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXPLORATORY BEHAVIOR; FEMALE; HEART RATE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; YOUNG ADULT;

EID: 84876057498     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2948-x     Document Type: Article

References (77)

1. Allman AA, Benkelfat C, Durand F, Sibon I, Dagher A, Leyton M, Baker GB, O'Driscoll GA (2010) Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacol (Berl) 211(4):423-433
2. Barch DM (2010) Pharmacological strategies for enhancing cognition in schizophrenia. Curr Top Behav Neurosci 4:43-96
3. Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:43-58
4. Barch DM, Carter CS (2008) Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative. Schizophr Bull 34:613-618
5. Barnett AG, van der Pols JC, Dobson AJ (2005) Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34:215-220. doi: 10.1093/ije/dyh299
6. Becker JB, Molenda H, Hummer DL (2001) Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Ann N Y Acad Sci 937:172-187
7. Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH (1996) Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat Genet 12:81-84
8. Bitsios P, Giakoumaki SG, Frangou S (2005) The effects of dopamine agonists on prepulse inhibition in healthy men depend on baseline PPI values. Psychopharmacol (Berl) 182(1):144-152
9. Bobo WV, Woodward ND, Sim MY, Jayathilake K, Meltzer HY (2011) The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr Res 130:106-113
10. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211-218
11. Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD (2008) Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 63:505-511
12. Buchanan RW, Keefe RSE, Umbricht D, Green MF, Laughren T, Marder SR (2011) The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 37:1209-1217
13. Bunney WE, Hetrick WP, Bunney BG, Patterson JV, Jin Y, Potkin SG, Sandman CA (1999) Structured Interview for Assessing Perceptual Anomalies (SIAPA). Schizophr Bull 25:577-592
14. Cervellione KL, Burdick KE, Cottone JG, Rhinewine JP, Kumra S (2007) Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome. J Am Acad Child Adolesc Psychiatry 46:867-878
15. Cloninger CR (1987) A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44:573-588
16. Corr PJ, Kumari V (2000) Individual differences in mood reactions to d-amphetamine: a test of three personality factors. J Psychopharmacol 14(4):371-377
17. Correll CU, Kishimoto T, Kane JM (2011) Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci 13:155-172
18. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907-1917
19. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH (1996) Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 12:78-80
20. Emanuel EJ, Miller FG (2001) The ethics of placebo-controlled trials - a middle ground. N Engl J Med 345:915-919
21. Ersche KD, Roiser JP, Lucas M, Domenici E, Robbins TW, Bullmore ET (2011) Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology 214:779-789. doi: 10.1007/s00213-010-2087-1
22. Eysenck H, Eysenck S (1994) Manual of the Eysenck personality questionnaire; comprising the EPQ-revised (EPQ-R) & EPQ-R short scale. Edits, San Diego
23. Fleming K, Bigelow LB, Weinberger DR, Goldberg TE (1995) Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol Bull 31:357-362
24. Giakoumaki SG, Roussos P, Bitsios P (2008) Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 33:3058-3068
25. Goff DC, Keefe R, Citrome L et al (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27:582-589. doi: 10.1097/jcp.0b013e31815abf34
26. Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159:1395-1402
27. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE (1991) Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148:78-84
28. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26:119-136
29. Hamidovic A, Dlugos A, Palmer AA, de Wit H (2010) Catechol-O- methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet 20:85-92. doi: 10.1097/YPG.0b013e32833a1f3c
30. Hamidovic A, Dlugos A, Skol A, Palmer AA, de Wit H (2009) Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. Exp Clin Psychopharmacol 17(6):374-383. doi: 10.1037/a0017840
31. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS (2011) Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 127:188-194. doi: 10.1016/j.schres.2011.01.004
32. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-445
33. Heinrichs RW, Ammari N, Miles AA, McDermid Vaz S (2010) Cognitive performance and functional competence as predictors of community independence in schizophrenia. Schizophr Bull 36:381-387. doi: 10.1093/schbul/sbn095
34. Hills T, Hertwig R (2011) Why aren't we smarter already: evolutionary trade-offs and cognitive enhancements. Curr Dir Psychol Sci 20:373-377
35. Hutchison KE, Wood MD, Swift R (1999) Personality factors moderate subjective and psychophysiological responses to d-amphetamine in humans. Exp Clin Psychopharmacol 7:493-501
36. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR (2012) Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 136:25-31. doi: 10.1016/j.schres.2011.11.001
37. Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS (2010) Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry 71:1475-1481
38. Keefe R, Harvey P (2012) Cognitive impairment in Schizophrenia. Handbook of experimental pharmacology: novel anti-Schizophrenia treatments. Springer:Berlin. doi: 10.1007/978-3-642-25758-2-2
39. Keefe RS, Fox KH, Harvey PD, Cuccchiaro J, Siu C, Loebel A (2011) Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125:161-168. doi: 10.1016/j.schres.2010.09.015
40. Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A (2010) What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36:504-509
41. Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, Sugar CA, Marder SR (2011) The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res 126(1-3):124-131
42. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR (2008) The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 165:214-220. doi: 10.1176/appi.ajp.2007.07010043
43. Kimberg DY, D'Esposito M (2003) Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 41:1020-1027
44. Kimberg DY, D'Esposito M, Farah MJ (1997) Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 8:3581-3585
45. Koychev I, McMullen K, Lees J, Dadhiwala R, Grayson L, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, Ettinger U, Wilkinson L, Williams S, Deakin JF, Barkus E (2012) A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study. Eur Neuropsychopharmacol 22(7):469-481
46. Kumari V, Cotter PA, Mulligan OF, Checkley SA, Gray NS, Hemsley DR, Thornton JC, Corr PJ, Toone BK, Gray JA (1999) Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. J Psychopharmacol 13:398-405
47. Kumari V, Ffytche DH, Williams SCR, Gray JA (2004) Personality predicts brain responses to cognitive demands. J Neurosci 24:10636-10641. doi: 10.1523/JNEUROSCI.3206-04.2004
48. Laurent A, Gilvarry C, Russell A, Murray R (2002) Personality dimensions and neuropsychological performance in first-degree relatives of patients with schizophrenia and affective psychosis. Schizophr Res 55:239-248
49. Marx CE, Keefe RSE, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ (2009) Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 34:1885-1903. doi: 10.1038/npp.2009.26
50. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage 12:268-275
51. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100:6186-6191
52. McClure MM, Bowie CR, Patterson TL, Heaton RK, Weaver C, Anderson H, Harvey PD (2007) Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophr Res 89:330-338
53. Mehta MA, Swainson R, Ogilvie AD, Sahakian J, Robbins TW (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Psychopharmacology 159:10-20
54. Nesselroade JR, Stigler SM, Baltes PB (1980) Regression toward the mean and the study of change. Psychol Bull 88:622-637
55. Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10:181-191
56. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008) The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165:203-213. doi: 10.1176/appi.ajp.2007.07010042
57. Patel MX (2003) Challenges in recruitment of research participants. Adv Psychiatr Treat 9:229-238
58. Pietrzak RH, Snyder PJ, Maruff P (2010a) Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum psychopharmacol 25:353-358. doi: 10.1002/hup.1118
59. Pietrzak RH, Snyder PJ, Maruff P (2010b) Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophr Res 124(1-3):176-182
60. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ (1980) Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943
61. 8F]fallypride. Synapse 65:99-102. doi: 10.1002/syn.20822
62. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH, the CSP 555 Research Group (2011) Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clin Trials 8:196-204
63. Roussos P, Giakoumaki SG, Bitsios P (2009) Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O- methyltransferase rs4818c/g polymorphism. Biol Psychiatry 66:997-1004
64. Scoriels L, Barnett JH, Soma PK, Sahakian BJ, Jones PB (2012) Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 220:249-258
65. Smith AP (1992) Effects of time of day, introversion and neuroticism on selectivity in memory and attention. Percept Mot Skills 74:851-860
66. Soubelet A, Salthouse TA (2011) Personality-cognition relations across adulthood. Dev Psychol 47:303-310
67. Swerdlow NR (2011) Are we studying and treating schizophrenia correctly? Schizophr Res 130:1-10. doi: 10.1016/j.schres.2011.05.004
68. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, Cadenhead K, Auerbach PP (2002) Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacol 161:189-201
69. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Shoemaker J, Auerbach PP (2003a) Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology 28:640-650. doi: 10.1038/sj.npp.1300086
70. Swerdlow NR, Wasserman LC, Talledo JA, Casas R, Bruins P, Stephany NL (2003b) Prestimulus modification of the startle reflex: relationship to personality and physiological markers of dopamine function. Biol Psychol 62:17-26
71. Swerdlow NR, Talledo J, Sutherland AN, Nagy D, Shoemaker JM (2006) Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology 31:2011-2021
72. Swerdlow NR, van Bergeijk DP, Bergsma F, Weber E, Talledo J (2009) The effects of memantine on prepulse inhibition. Neuropsychopharmacology 34:1854-1864
73. Talledo JA, Sutherland Owens AN, Schortinghuis T, Swerdlow NR (2009) Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology 204:165-175. doi: 10.1007/s00213-008-1446-7
74. Touwen DP, Engberts DP (2012) Those famous red pills-Deliberations and hesitations. Ethics of placebo use in therapeutic and research settings. Eur Neuropsychopharmacol [Epub ahead of print, April 23]
75. White TL, Lott DC, de Wit H (2006) Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology 31:1064-1074. doi: 10.1038/sj.npp.1300939
76. Williams LM, Whitford TJ, Flynn G, Wong W, Liddell BJ, Silverstein S, Galletly C, Harris AW, Gordon E (2008) General and social cognition in first episode schizophrenia: identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. Schizophr Res 99:182-191
77. Zuckerman M, Bone RN, Neary R, Mangelsdorff D, Brustman B (1972) What is the sensation seeker? Personality trait and experience correlates of the Sensation-Seeking Scales. J Consult Clin Psychol 39:308-321